SCHEMBL12434249

SCHEMBL12434249

O=C(NCc1ccccc1-c1ccccc1C(=O)NCc1ccccn1)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SORT1 Q99523 1/20 0.54
NPC1 O15118 3/20 0.54
RAB9A P51151 2/20 0.54
KMT2A Q03164 3/20 0.53
LMNA P02545 2/20 0.53
HTT P42858 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KCNA5 P22460 2/20 0.50
SMO Q99835 1/20 0.50
ALOX15 P16050 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NAMPT P43490 1/20 0.48
PKM P14618 1/20 0.48
GLA P06280 1/20 0.47
MAPT P10636 1/20 0.47
KCNK3 O14649 1/20 0.47
KCNA3 P22001 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12434271 0.92 KCNA5 (0.58) SORT1NPC1RAB9AKMT2AL3MBTL1
SCHEMBL20379672 0.85 NPC1 (0.72) NPC1RAB9AKMT2AHTTL3MBTL1
SCHEMBL12434277 0.82 KCNA5 (0.56) SORT1NPC1RAB9AKMT2ALMNA
SCHEMBL6795684 0.80 SMO (0.65) SORT1NPC1RAB9AKMT2ALMNA
SCHEMBL2208589 0.80 KCNA5 (0.68) NPC1RAB9AKMT2ALMNAHTT
SCHEMBL12434268 0.79 CNR1 (0.68) NPC1RAB9AKMT2AHTTKCNA5
SCHEMBL12434275 0.78 KMT2A (0.52) NPC1RAB9AKMT2ALMNAHTT
SCHEMBL6794043 0.77 SMO (0.61) SORT1KMT2ALMNAHTTL3MBTL1
SCHEMBL12434263 0.77 KCNA5 (0.55) NPC1RAB9AKMT2AHTTKCNA5
SCHEMBL12434243 0.77 KCNA5 (0.61) NPC1RAB9AKMT2AL3MBTL1KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E SORT1 4763/4885NPC1 3604/4885RAB9A 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.